via Lancet.com, by Salim S Abdool Karim  and Quarraisha Abdool Karim On May 10, 2012, a US Food and Drug Administration (FDA) advisory committee voted in support of the use of tenofovir-emtricitabine for HIV prevention.1 If the FDA, which is scheduled to make its decision by June 15, adopts the committee’s recommendations, tenofovir-emtricitabine will become the first Read More >>

via RH Reality Check, by Anna Forbes and Kate Ryan People who participate in clinical trials take the enormous step of volunteering to test a product that may be useful and, sometimes, life-saving if it turns out to be effective. They play an irreplaceable role in research to prevent, treat, and sometimes cure illness – as well Read More >>

via the Treatment Action Campaign (TAC), by Catherine Tomlinson and Nathan Geffen Exciting new evidence has demonstrated the potential of antiretroviral medicines (ARVs) to prevent HIV from being sexually transmitted. This TAC briefing explains the evidence and then discusses policy implications. Our recommendations 1.The WHO must release its guidelines on serodiscordant couples.2.People living with HIV should be Read More >>

via Science, by Anthony S. Fauci Thirty years have passed since the first cases of acquired immune deficiency syndrome (AIDS) were reported by the U.S. Centers for Disease Control and Prevention. How does this anniversary compare to the 20th or the 10th? The differences are considerable, because we now have an unprecedented opportunity, based on solid scientific Read More >>

via Bloomberg AIDS has been with us, officially, for 30 years, since the U.S. Centers for Disease Control and Prevention reported the first cases. This unhappy anniversary is perhaps as good a time as any to spell out why the global response to AIDS is in need of serious adjustment. Annual spending on AIDS worldwide has risen Read More >>

via PlusNews A three-month campaign by Addis Ababa’s health bureau hopes to boost adherence to antiretroviral (ARVs) drugs in the Ethiopian capital by improving communication between patients and health service providers. A 2009 study by the HIV/AIDS Prevention and Control Office found that on average, 72.3 percent of patients on ARVs were still on first-line medication one Read More >>

Via aidsmap, by Carole Leach-Lemens Patients in Nairobi, Kenya getting intensive early adherence counselling when starting antiretroviral therapy were 29% less likely to have poor adherence and 59% less likely to have virological failure compared to those getting no counselling Michael H Chung and colleagues reported in a randomised, controlled trial published in the March issue of Read More >>

Via aidsmap, by Michael Carter Universal adult access to antiretroviral therapy compared to current roll-out could prevent over 4 million more children being orphaned because of HIV in the sub-Saharan African countries hardest hit by AIDS, according to published in the online journal AIDS Research and Therapy. “Results from this study highlight the positive impact that expanded Read More >>